Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has received clearance from the U.S. Food and Drug Administration (FDA) to advance its lead multiple sclerosis (MS) candidate, Lucid-MS (Lucid-21-302), into Phase 2 clinical development. The approval of the Investigational New Drug (IND) application marks a significant milestone for the company, which is positioning Lucid-MS as a potential first-in-class therapy that directly targets the underlying neurodegenerative processes of MS.
Unlike current MS treatments that focus on modulating the immune system to reduce inflammation, Lucid-MS is designed to provide neuroprotection by inhibiting demyelination—the process by which the protective myelin sheath around nerve fibers is damaged. The drug targets protein arginine deiminase 2 (PAD2), an enzyme implicated in myelin degradation. In preclinical models, Lucid-MS has demonstrated the ability to prevent and reverse myelin breakdown, a differentiating feature that could address the progressive nature of MS.
The upcoming Phase 2 study will be a randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy, safety, and tolerability of Lucid-MS in people with MS. The trial will use both clinical and radiological measures to assess outcomes. According to the company, trial start-up activities, including site selection, are already underway, with patient enrollment and drug administration expected to begin as quickly as possible.
This regulatory milestone comes on the heels of a favorable safety profile observed in Phase 1 trials, where Lucid-MS was well tolerated in healthy participants. The company also reported having more than $10 million in cash, digital assets, and liquid investments as of March 31, 2026, which may provide the financial runway needed to initiate and conduct the Phase 2 trial.
The significance of this development extends beyond Quantum BioPharma. For the MS community, the potential availability of a therapy that directly targets demyelination could represent a paradigm shift in treatment. Existing disease-modifying therapies primarily reduce relapses by dampening immune responses, but they have limited impact on disability progression. Lucid-MS's neuroprotective approach aims to slow or even reverse the damage caused by MS, which could improve long-term outcomes for patients.
From an investment perspective, the FDA's clearance reduces regulatory uncertainty and validates the scientific rationale behind Lucid-MS. It also opens the door to potential partnerships or licensing deals, as larger pharmaceutical companies may see value in a candidate with a novel mechanism of action. However, the drug is still in early-stage development, and Phase 2 results will be critical in determining its true therapeutic potential.
Quantum BioPharma is dedicated to building a portfolio of innovative assets for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is focused on the research and development of Lucid-MS. Additionally, the company retains a 19.84% stake in Unbuzzd Wellness Inc., the maker of the hangover remedy UNBUZZD(TM), and is entitled to royalty payments from its sales.
The announcement was disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. For more information on the full press release, visit https://ibn.fm/HyWYH.
